In an adult who has been abstinent from cocaine for more than one month and now presents with severe depression and anxiety, what is the initial treatment of choice?

Initial Treatment for Severe Depression and Anxiety After Cocaine Abstinence

For an adult who has been abstinent from cocaine for over one month and now presents with severe depression and anxiety, initiate treatment with an SSRI (such as sertraline 50 mg daily) combined with Contingency Management plus Community Reinforcement Approach (CM+CRA) as the psychosocial intervention. 1, 2

Rationale for Combined Pharmacotherapy and Psychosocial Treatment

The evidence strongly supports combining medication with structured behavioral therapy rather than using either approach alone:

• Combined cognitive behavioral therapy and pharmacotherapy demonstrates superior outcomes compared to usual care, with effect sizes of g=0.18-0.28 for substance use outcomes 3
• Depression improvement is directly associated with improvement in cocaine use patterns, making treatment of the mood disorder essential for sustained recovery 4
• Delivering psychotherapy concurrently (not sequentially) with pharmacotherapy is critical for optimal outcomes 5

Pharmacological Management of Depression and Anxiety

First-Line Antidepressant Selection

• Start sertraline 50 mg once daily (morning or evening) for major depressive disorder 2
• Sertraline is FDA-approved for depression, anxiety disorders (panic disorder, PTSD, social anxiety disorder), and has a well-established safety profile 2
• Patients not responding to 50 mg may benefit from dose increases up to 200 mg/day, with changes made at intervals of at least 1 week given the 24-hour elimination half-life 2

Alternative Antidepressant Considerations

• Desipramine (tricyclic antidepressant) has specific evidence in cocaine-dependent patients with depression, showing a 51% depression response rate versus 32% with placebo 4
• However, desipramine carries higher dropout rates due to side effects and medical adverse events compared to placebo 4
• Mirtazapine may be considered as it has demonstrated effectiveness in reducing both depression and anxiety-like behaviors during cocaine withdrawal in preclinical studies 6

Evidence for Treating Depression in This Population

• Depressed cocaine-dependent patients treated with antidepressants show dramatic reductions: 84% decrease in cocaine usage versus 17% with placebo, and 48% decrease in cocaine craving versus 29% increase with placebo 7
• Depression is the most common psychiatric disorder in substance abusers and results in poorer prognosis when untreated 7
• Baseline depression severity predicts better response to structured psychotherapy (relapse prevention) compared to clinical management alone 8

Psychosocial Treatment: CM Plus CRA as First-Line

Why CM+CRA is the Gold Standard

• CM plus CRA is the most effective psychosocial intervention with a number needed to treat (NNT) of 3.7 (95% CI 2.4-14.2) for sustained abstinence 1
• This combination was superior to all other interventions at end of treatment (OR 2.84,95% CI 1.24-6.51), at 12 weeks (OR 7.60,95% CI 2.03-28.37), and at longest follow-up (OR 3.08,95% CI 1.33-7.17) 3
• CM+CRA showed fewer dropouts than treatment as usual both at 12 weeks (OR 3.92) and end of treatment (OR 3.63) 3

Components of the Combined Approach

Contingency Management (CM):

• Provides tangible rewards (vouchers or prizes) contingent upon drug-free urine samples 1
• Creates immediate positive reinforcement for abstinence 1
• Requires regular urine drug screening throughout treatment 1

Community Reinforcement Approach (CRA):

• Multi-layered intervention involving functional analysis of substance use triggers 1
• Coping-skills training for managing cravings and high-risk situations 1
• Social, familial, recreational, and vocational reinforcements to build a life incompatible with substance use 1

Alternative Psychosocial Options When CM+CRA Unavailable

• Cognitive Behavioral Therapy (CBT) is the second-line option with NNT of 10.5 (95% CI 5.8-53.6) for dropout reduction 1
• CBT combined with pharmacotherapy shows benefit over usual care (g=0.18 for frequency outcomes, g=0.28 for quantity outcomes) 3
• CBT must be delivered concurrently with medication, not sequentially 5

Critical Pitfalls to Avoid

Do Not Use Monotherapy Approaches

• Never rely solely on CM without CRA, as this leads to relapse after treatment completion when behavioral reinforcement is withdrawn 1, 5
• Do not use pharmacotherapy alone without integrated behavioral interventions, as combined treatment is consistently superior 3, 5
• Avoid using non-contingent rewards (providing rewards regardless of drug use status), which have not shown effectiveness 3

Medication-Specific Cautions

• No medications are FDA-approved specifically for cocaine use disorder; psychosocial interventions remain first-line for the addiction component 1
• Do not prescribe adrenergic blockers if acute cocaine toxicity symptoms emerge, as they are contraindicated 9
• Avoid relying on 12-step programs as standalone treatment, though they may be beneficial as adjuncts 1

Treatment Duration and Follow-Up Errors

• Do not provide inadequate long-term follow-up, as sustained recovery requires ongoing support beyond initial treatment stabilization 1, 5
• Recognize that CM alone shows efficacy during active treatment but effects are not sustained at long-term follow-up without CRA 1
• Ensure at least 3 months of follow-up for longitudinal assessment 1

Monitoring Strategy

Psychiatric Monitoring

• Assess depression and anxiety symptoms biweekly using standardized scales (e.g., Hamilton Depression Scale) 4
• Monitor for psychiatric worsening, which is more common with placebo/inadequate treatment than with active antidepressant therapy 4
• Track cocaine craving levels weekly, as these correlate with relapse risk 4

Substance Use Monitoring

• Conduct regular urine drug screens to provide objective evidence of abstinence and implement CM effectively 1
• Self-reported cocaine use should be collected weekly but verified with toxicology 4
• Monitor for longest duration of continuous abstinence as a key outcome measure 3

Medical Monitoring

• Continued assessment for cardiovascular complications is necessary throughout treatment given cocaine's cardiac effects 1, 9
• Monitor for hyperthermia if any acute cocaine use occurs, as it increases cocaine toxicity 9
• Assess for neurological disorders and cognitive deficits that may complicate treatment adherence 1

Treatment Timeline and Expectations

• Acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy beyond response to the acute episode 2
• Antidepressant dose changes should not occur at intervals less than 1 week given sertraline's 24-hour elimination half-life 2
• The combination of CM+CRA typically requires 12-24 weeks of active treatment 3
• Higher-severity patients have significantly better outcomes with structured relapse prevention compared to clinical management alone 8